^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1d
    Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (clinicaltrials.gov)
    P1/2, N=20, Recruiting, University Hospital Tuebingen | Trial completion date: Mar 2027 --> Feb 2029 | Trial primary completion date: Mar 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    TP53 mutation • CD19 positive
    |
    Monjuvi (tafasitamab-cxix)
    7d
    An early clinical study to evaluate the safety and clinical efficacy of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia (ChiCTR2500111445)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    7d
    Complete remission treated by Bcl-2 inhibitor combined with Blinatumomab as induction treatment for adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation: A multicenter, prospective, randomized controlled, open-label, phase II study (ChiCTR2500111430)
    P2, N=146, Not yet recruiting, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University
    New P2 trial
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    7d
    ATECRAB: T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (clinicaltrials.gov)
    P1, N=3, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> May 2025
    Trial completion • Trial completion date
    |
    CD19 positive
    8d
    A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1/2 trial
    |
    CD19 positive • CD20 negative
    11d
    Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide
    11d
    Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, The Second Affiliated Hospital of Fujian Medical University
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    14d
    To Evaluate the Safety and Tolerability of STR-P004 for the Treatment of Immune-mediated Kidney Diseases (clinicaltrials.gov)
    P=N/A, N=9, Not yet recruiting, Starna Therapeutics
    New trial
    |
    CD19 positive
    15d
    m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis. (PubMed, Front Immunol)
    Furthermore, m-EASIX accurately distinguished CRS from sepsis at symptom onset. m-EASIX is a practical and accessible tool for the early prediction of severe CAR T-cell-related toxicities, risk stratification, and differential diagnosis from sepsis, offering potential to guide clinical decision-making and early intervention.
    Journal • IO biomarker
    |
    CRP (C-reactive protein)
    |
    CD19 positive
    15d
    CD19 CART CELL: CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, King Faisal Specialist Hospital & Research Center
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    16d
    Anti CD19 Gene Therapy for B-cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=18, Recruiting, Anhui Provincial Hospital | Initiation date: Oct 2025 --> Mar 2026
    Trial initiation date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD19 positive
    16d
    Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 positive
    |
    Tyvyt (sintilimab) • cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)